
CMS Statement on FDA Accelerated Approval of Lecanemab
CMS is releasing the following statement from Administrator Chiquita Brooks-LaSure, with accompanying background information, in response to the action by the FDA to grant accelerated approval to a new product designed to treat Alzheimer’s disease.